Another QMSR Town Hall – What Changes and What Stays the Same in FDA’s Inspection Process

Key Takeaways

• FDA will assess risk management documents across the entire QMS
• Model 1 inspections cover minimum elements; Model 2 inspect all elements
• Statistical sampling is eliminated; inspectors select records based on product risk
• Management, internal, and supplier audit records now fall within inspection scope
• Culture of quality judged by risk‑based decisions, not separate documentation

Pulse Analysis

The FDA’s Quality Management System Regulation (QMSR) compliance date of February 2, 2026 is fast approaching, and the agency’s recent town hall provides a roadmap for manufacturers. By shifting from the legacy Quality System Inspection Technique (QSIT) to a risk‑centric model, the FDA expects firms to embed risk‑management files—hazard analyses, control plans, and effectiveness evidence—throughout every quality function. This approach aligns with ISO 13485 clause 7.1 but expands the expectation that even administrative processes reference product‑level risk documentation, reducing the need for separate risk assessments for tasks like training or document control.

Inspection mechanics will retain familiar elements such as the Form 482 pre‑inspection questionnaire, on‑site tours, and the issuance of Form 483 for observations. However, the new Inspection of Medical Device Manufacturers Compliance Program Manual (CP‑7382.850) eliminates the statistical sampling requirement, granting inspectors discretion to review records based on device risk and their professional judgment. Model 1 inspections will cover at least one element in each QMS area, while Model 2 inspections demand a comprehensive review of all elements. Crucially, the scope now encompasses management review minutes, internal audit reports, and supplier audit records—areas previously outside the inspector’s purview.

For device makers, the practical impact is clear: quality systems must be holistically documented and demonstrably risk‑driven. Companies should audit their QMS to ensure risk controls are visible in design, production, and post‑market activities, and that audit programs evaluate the integration of risk management. Emphasizing a culture of quality through consistent, risk‑based decision‑making will be the most persuasive evidence for regulators, reducing the likelihood of enforcement actions that could stall market entry. Proactive alignment with the CP now positions manufacturers to meet the 2026 deadline with confidence.